Michael D. Croghan
Amgen (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Drug Transport and Resistance Mechanisms, Carbohydrate Chemistry and Synthesis, Pancreatic function and diabetes, Sphingolipid Metabolism and Signaling
Most-Cited Works
- → Design and Preparation of a Potent Series of Hydroxyethylamine Containing β-Secretase Inhibitors That Demonstrate Robust Reduction of Central β-Amyloid(2012)64 cited
- → Design of a new peptidomimetic agonist for the melanocortin receptors based on the solution structure of the peptide ligand, Ac-Nle-cyclo[Asp-Pro-dPhe-Arg-Trp-Lys]-NH2(2003)42 cited
- → Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors(2012)41 cited
- → Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase–Glucokinase Regulatory Protein (GK–GKRP) Binding: Strategic Use of a N → S (nN → σ*S–X) Interaction for Conformational Constraint(2015)40 cited
- → Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for in Vivo Proof-of-Concept(2014)33 cited
- → Stereoselective Synthesis ofanti-N-Protected 3-Amino-1,2-epoxides by Nucleophilic Addition toN-tert-Butanesulfinyl Imine of a Glyceraldehyde Synthon†(2009)30 cited
- → A Potent and Orally Efficacious, Hydroxyethylamine-Based Inhibitor of β-Secretase(2012)28 cited
- → 4-Methoxy-N-[2-(trifluoromethyl)biphenyl-4-ylcarbamoyl]nicotinamide: A Potent and Selective Agonist of S1P1(2011)20 cited
- → Quinolinone-based agonists of S1P1: Use of a N-scan SAR strategy to optimize in vitro and in vivo activity(2011)17 cited
- → Optimization of a Potent, Orally Active S1P1 Agonist Containing a Quinolinone Core(2011)16 cited